INTRAVITREAL RANIBIZUMAB THERAPY for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION and the RISK of STROKE

A National Sample Cohort Study

Tyler Hyungtaek Rim, Christopher Seungkyu Lee, Sungchul Lee, Do Wook Kim, Sung Soo Kim

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: To evaluate the risk of stroke after ranibizumab treatment for neovascular age-related macular degeneration. Methods: National registry data for 1,025,340 random subjects in the year 2002 were used. The ranibizumab group comprised patients diagnosed with neovascular age-related macular degeneration and treated with ranibizumab between 2009 and 2013 (n 467). The two types of comparison groups were defined as comorbidity-matched controls (n 2,330) comprised of randomly selected patients (5 per age-related macular degeneration patient), who were matched to the ranibizumab group according to sociodemographic factors, hypertension, atrial fibrillation, and the Charlson comorbidities index, and sociodemographic-matched controls (n 2,331) matched according to sociodemographic factors only. Each sampled patient was tracked until 2013. The Cox proportional hazard regression was used. Results: Stroke occurred in 6.6% of the ranibizumab group versus 7.0% of the comorbidity-matched controls and 6.7% of the sociodemographic-matched controls; these differences were not statistically significant. The overall incidence of stroke was similar for the ranibizumab group versus the comorbidity-matched controls and sociodemographic-matched controls, based on the multivariable Cox regression (hazard ratio 0.88; 95% confidence interval, 0.60-1.30; hazard ratio 0.95, 95% confidence interval, 0.64-1.41, respectively). Conclusion: Ranibizumab treatment for neovascular age-related macular degeneration did not increase the overall risk of stroke, compared with comorbidity-matched controls or sociodemographic-matched controls.

Original languageEnglish
Pages (from-to)2166-2174
Number of pages9
JournalRetina
Volume36
Issue number11
DOIs
Publication statusPublished - 2016 Nov 1

Fingerprint

Macular Degeneration
Cohort Studies
Comorbidity
Stroke
Therapeutics
Confidence Intervals
Ranibizumab
Atrial Fibrillation
Registries
Hypertension
Incidence

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Rim, Tyler Hyungtaek ; Lee, Christopher Seungkyu ; Lee, Sungchul ; Kim, Do Wook ; Kim, Sung Soo. / INTRAVITREAL RANIBIZUMAB THERAPY for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION and the RISK of STROKE : A National Sample Cohort Study. In: Retina. 2016 ; Vol. 36, No. 11. pp. 2166-2174.
@article{9956df50b96e4cf994f6551a9a5b818a,
title = "INTRAVITREAL RANIBIZUMAB THERAPY for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION and the RISK of STROKE: A National Sample Cohort Study",
abstract = "Purpose: To evaluate the risk of stroke after ranibizumab treatment for neovascular age-related macular degeneration. Methods: National registry data for 1,025,340 random subjects in the year 2002 were used. The ranibizumab group comprised patients diagnosed with neovascular age-related macular degeneration and treated with ranibizumab between 2009 and 2013 (n 467). The two types of comparison groups were defined as comorbidity-matched controls (n 2,330) comprised of randomly selected patients (5 per age-related macular degeneration patient), who were matched to the ranibizumab group according to sociodemographic factors, hypertension, atrial fibrillation, and the Charlson comorbidities index, and sociodemographic-matched controls (n 2,331) matched according to sociodemographic factors only. Each sampled patient was tracked until 2013. The Cox proportional hazard regression was used. Results: Stroke occurred in 6.6{\%} of the ranibizumab group versus 7.0{\%} of the comorbidity-matched controls and 6.7{\%} of the sociodemographic-matched controls; these differences were not statistically significant. The overall incidence of stroke was similar for the ranibizumab group versus the comorbidity-matched controls and sociodemographic-matched controls, based on the multivariable Cox regression (hazard ratio 0.88; 95{\%} confidence interval, 0.60-1.30; hazard ratio 0.95, 95{\%} confidence interval, 0.64-1.41, respectively). Conclusion: Ranibizumab treatment for neovascular age-related macular degeneration did not increase the overall risk of stroke, compared with comorbidity-matched controls or sociodemographic-matched controls.",
author = "Rim, {Tyler Hyungtaek} and Lee, {Christopher Seungkyu} and Sungchul Lee and Kim, {Do Wook} and Kim, {Sung Soo}",
year = "2016",
month = "11",
day = "1",
doi = "10.1097/IAE.0000000000001084",
language = "English",
volume = "36",
pages = "2166--2174",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

INTRAVITREAL RANIBIZUMAB THERAPY for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION and the RISK of STROKE : A National Sample Cohort Study. / Rim, Tyler Hyungtaek; Lee, Christopher Seungkyu; Lee, Sungchul; Kim, Do Wook; Kim, Sung Soo.

In: Retina, Vol. 36, No. 11, 01.11.2016, p. 2166-2174.

Research output: Contribution to journalArticle

TY - JOUR

T1 - INTRAVITREAL RANIBIZUMAB THERAPY for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION and the RISK of STROKE

T2 - A National Sample Cohort Study

AU - Rim, Tyler Hyungtaek

AU - Lee, Christopher Seungkyu

AU - Lee, Sungchul

AU - Kim, Do Wook

AU - Kim, Sung Soo

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Purpose: To evaluate the risk of stroke after ranibizumab treatment for neovascular age-related macular degeneration. Methods: National registry data for 1,025,340 random subjects in the year 2002 were used. The ranibizumab group comprised patients diagnosed with neovascular age-related macular degeneration and treated with ranibizumab between 2009 and 2013 (n 467). The two types of comparison groups were defined as comorbidity-matched controls (n 2,330) comprised of randomly selected patients (5 per age-related macular degeneration patient), who were matched to the ranibizumab group according to sociodemographic factors, hypertension, atrial fibrillation, and the Charlson comorbidities index, and sociodemographic-matched controls (n 2,331) matched according to sociodemographic factors only. Each sampled patient was tracked until 2013. The Cox proportional hazard regression was used. Results: Stroke occurred in 6.6% of the ranibizumab group versus 7.0% of the comorbidity-matched controls and 6.7% of the sociodemographic-matched controls; these differences were not statistically significant. The overall incidence of stroke was similar for the ranibizumab group versus the comorbidity-matched controls and sociodemographic-matched controls, based on the multivariable Cox regression (hazard ratio 0.88; 95% confidence interval, 0.60-1.30; hazard ratio 0.95, 95% confidence interval, 0.64-1.41, respectively). Conclusion: Ranibizumab treatment for neovascular age-related macular degeneration did not increase the overall risk of stroke, compared with comorbidity-matched controls or sociodemographic-matched controls.

AB - Purpose: To evaluate the risk of stroke after ranibizumab treatment for neovascular age-related macular degeneration. Methods: National registry data for 1,025,340 random subjects in the year 2002 were used. The ranibizumab group comprised patients diagnosed with neovascular age-related macular degeneration and treated with ranibizumab between 2009 and 2013 (n 467). The two types of comparison groups were defined as comorbidity-matched controls (n 2,330) comprised of randomly selected patients (5 per age-related macular degeneration patient), who were matched to the ranibizumab group according to sociodemographic factors, hypertension, atrial fibrillation, and the Charlson comorbidities index, and sociodemographic-matched controls (n 2,331) matched according to sociodemographic factors only. Each sampled patient was tracked until 2013. The Cox proportional hazard regression was used. Results: Stroke occurred in 6.6% of the ranibizumab group versus 7.0% of the comorbidity-matched controls and 6.7% of the sociodemographic-matched controls; these differences were not statistically significant. The overall incidence of stroke was similar for the ranibizumab group versus the comorbidity-matched controls and sociodemographic-matched controls, based on the multivariable Cox regression (hazard ratio 0.88; 95% confidence interval, 0.60-1.30; hazard ratio 0.95, 95% confidence interval, 0.64-1.41, respectively). Conclusion: Ranibizumab treatment for neovascular age-related macular degeneration did not increase the overall risk of stroke, compared with comorbidity-matched controls or sociodemographic-matched controls.

UR - http://www.scopus.com/inward/record.url?scp=84976299790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976299790&partnerID=8YFLogxK

U2 - 10.1097/IAE.0000000000001084

DO - 10.1097/IAE.0000000000001084

M3 - Article

VL - 36

SP - 2166

EP - 2174

JO - Retina

JF - Retina

SN - 0275-004X

IS - 11

ER -